Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
1.800
-0.030 (-1.64%)
At close: Jun 5, 2025, 4:00 PM
1.790
-0.010 (-0.55%)
After-hours: Jun 5, 2025, 7:59 PM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $49.32M in the quarter ending March 31, 2025, with 6,798.46% growth. This brings the company's revenue in the last twelve months to $212.68M, up 11,070.12% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm)
$212.68M
Revenue Growth
+11,070.12%
P/S Ratio
2.62
Revenue / Employee
$253,794
Employees
838
Market Cap
601.08M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
IOVA News
- 1 day ago - IOVA LAWSUIT: Iovance Biotherapeutics, Inc. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law - Accesswire
- 2 days ago - IOVA STOCK NOTICE: Iovance Biotherapeutics, Inc. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 14 Legal Deadline - Accesswire
- 3 days ago - IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - PRNewsWire
- 3 days ago - The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma - GlobeNewsWire
- 5 days ago - IOVA CLASS NOTICE: Iovance Biotherapeutics, Inc. Investors may have been Affected by Fraud – Contact BFA Law before July 14 Court Deadline (NASDAQ:IOVA) - GlobeNewsWire
- 7 days ago - Scott+Scott Attorneys at Law LLP Continues to Remind Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) - GlobeNewsWire
- 11 days ago - IOVA FRAUD: Suffer Losses on Iovance Biotherapeutics, Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:IOVA) - GlobeNewsWire
- 13 days ago - IOVA FRAUD NEWS: Iovance Biotherapeutics, Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by July 14 Court Deadline - Accesswire